Scott Holbrook

Chief Strategy Officer & GM, PET & Precision Medicine at PharmaLogic Holdings

Scott has over twenty years’ experience in the field of molecular imaging and therapeutics which encompasses all phases of radiopharmaceutical drug development including target identification, GMP manufacturing, clinical trials, translation, and post-approval manufacturing.

Scott started his industry career at PETNET Solutions. Since then he has co-founded Precision Nuclear and Invivo Imaging, now owned by PharmaLogic Holdings. He has served on more than fifty internationally recognized committees and boards of directors established by international medical societies and government agencies in molecular imaging. He has served as the president of the Society of Nuclear Medicine and Molecular Imaging-TS on two occasions and has spent five years on the SNMMI board of directors and is experienced in working with FDA, CMS, the US Congress, The Joint Commission, The Nuclear Regulatory Commission, (NRC), The Conference of Radiation Control Program Directors (CRCPD). Scott holds a Bachelor of Science degree in nuclear medicine technology and a Master of Science degree in molecular imaging and therapeutics.

Links